Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NBI-1117570 in Adults With Schizophrenia Who Warrant Inpatient Hospitalization
NCT07288333Phase 2Recruiting
- Sponsor
- Neurocrine Biosciences
- Start
- Feb 2026
- Primary completion
- Aug 2027
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 2 trial of NBI-1117570 in schizophrenia, sponsored by Neurocrine Biosciences. Started Feb 2026; status: recruiting.
02
Drugs
NBI-1117570
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT07288333.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07288333.